Ezetimibe; Ezetimibe With Simvastatin
Recommended · restricted CardiovascularAuthority RequiredSecond-line line
Addition of symptomatic peripheral vascular disease and heterozygous familial hypercholesterolaemia to the ezetimibe listing for co-administration with a statin in patients whose cholesterol levels are inadequately controlled with a statin.
1
Submissions
1 resub
2005–05
On the record
$15k–45k
ICER range
1 sourced ICER · 2005
ICER stated
Cost basis
Access path
- Nov 2005Recommended · restricted
vs statin alone
- PBS listing · Authority Required
RecommendedDeferredNot recommended
Cost-effectiveness
The incremental cost/extra life year gained in cerebrovascular disease patients, peripheral vascular disease patients and HeFH patients was between $15,000-$45,000. PSD · 2005
Decision context
PopulationPatients with peripheral vascular disease or heterozygous familial hypercholesterolaemia whose cholesterol levels are inadequately controlled with a statin (defined as levels exceeding PBS threshold after ≥3 months treatment at ≥40 mg daily statin dose).
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2005 | Recommended · restricted | statin alone | $15k–45k | RCT · LDL-C |